73776-20-2

Usage

Uses

Used in Pharmaceutical Industry:
7-Quinolinecarboxylic acid, 8-hydroxy-, methyl ester (6CI, 9CI) serves as a crucial starting material in the production of pharmaceuticals. Its role is pivotal in the synthesis of various medicinal compounds due to its unique chemical structure.
Used in Agrochemical Industry:
In the agrochemical sector, 7-Quinolinecarboxylicacid,8-hydroxy-,methylester(6CI,9CI) acts as an essential building block for the development of different agrochemical products, contributing to its wide range of applications in this field.
Used as a Chelating Agent:
7-Quinolinecarboxylic acid, 8-hydroxy-, methyl ester (6CI, 9CI) has potential applications as a chelating agent, which allows it to form complexes with metal ions. This property makes it useful in various chemical processes that require the sequestration or separation of metal ions.
Used as a Precursor to Dyes:
7-Quinolinecarboxylicacid,8-hydroxy-,methylester(6CI,9CI) also functions as a precursor to the synthesis of various dyes, highlighting its versatility in the chemical industry and its ability to contribute to the colorants market.
Used in Organic Synthesis:
As a building block in organic synthesis, 7-Quinolinecarboxylic acid, 8-hydroxy-, methyl ester (6CI, 9CI) is instrumental in creating a diverse array of chemical products, showcasing its importance in the synthesis of complex organic molecules.

Upstream product

• 67-56-1 methanol 
• 3724-55-8 methyl but-3-enoate 
• 53636-56-9 methyl 3-bromopicolinate 
• 19829-79-9 8-hydroxy-7-quinolinecarboxylic acid 

Downstream Products

• 1101929-86-5 C₁₈H₁₅NO₃ 
• 1101929-88-7 C₆₀H₄₈N₆O₁₂ 
• 1101929-87-6 C₁₇H₁₂FNO₂ 
• 630414-70-9 8-benzyloxyquinoline-7-carboxylic acid 
• 1374193-98-2 4-amino-6-((1-(8-(3,5-difluorophenyl)-7-quinolinyl)ethyl)amino)-5-pyrimidinecarbonitrile 
• 1374193-76-6 N-(1-(8-(3,5-difluorophenyl)quinolin-7-yl)ethyl)-2-methylpropane-2-sulfinamide 
• 1374193-62-0 (E)-N-((8-(3,5-difluorophenyl)quinolin-7-yl)methylene)-2-methylpropane-2-sulfinamide 
• 1374193-48-2 8-(3,5-difluorophenyl)quinoline-7-carbaldehyde 
• 1374193-41-5 (8-(3,5-difluorophenyl)quinolin-7-yl)methanol 
• 1374193-31-3 methyl 8-(3,5-difluorophenyl)quinoline-7-carboxylate 
• 1312682-38-4 N-(1-(8-(3,5-difluorophenyl)quinolin-7-yl)ethyl)-9H-purin-6-amine 
• 1312684-75-5 1-[8-(3,5-difluorophenyl)quinolin-7-yl]ethanamine 
• 1352717-26-0 5-[(6-chloropyridin-3-yl)methyl]-8-[(1S,2S)-2-hydroxycyclohexyl]-1,8-phenanthrolin-7(8H)-one 
• 1352717-49-7 5-bromo-8-((1S,2S)-2-hydroxycyclohexyl)-1,8-phenanthrolin-7(8H)-one 

Relevant academic research and scientific papers

Efficient Access to Methyl-1-hydroxy-2-naphthoates and Heterocyclic Analogues

We report the synthesis of methyl-1-hydroxy-2-naphthoate derivatives and heterocyclic analogues using a two-step approach. This short route employs a Heck coupling of a 2-halo-benzoate with methyl 3-butenoate followed by a Dieckmann cyclization, yielding the 1-hydroxynaphthalene-2-carboxylic acid derivatives in the multigram scale.

Electronic spectroscopic characterization of the formation of iron(III) metal complexes: The 8-HydroxyQuinoline as ligand case study

Synthetic siderophores derivated from 8-HydroxyQuinoline (HQ) present various biological and pharmacological activities, such as anti-neurodegenerative or anti-oxydative. However, their affinity towards iron(III) seems to depend on the position (i.e., 7 or 2) of the HQ substitution by an electron withdrawing group. Two ester-derivatives of HQ at 2- and 7-position are synthesized and their respective iron-complexation is characterized by a joined experimental and theoretical work. By investigating the stability of all the possible accessible spin states of the iron(III) complexes at density-functional theory (DFT) level, we demonstrate that the high-spin (HS) state is the most stable one, and leads to a UV/vis absorption spectrum in perfect match with experiments. From this DFT protocol, and in agreement with the experimental results, we show that the ester functionalization of HQ in 2-position weakens the formation of the iron(III) complex while its substitution in 7-position allows a salicylate coordination of the metal very close to the ideal octahedral environment.

Oxinobactin and sulfoxinobactin, abiotic siderophore analogues to enterobactin involving 8-hydroxyquinoline subunits: Thermodynamic and structural studies

The synthesis of two new iron chelators built on the tris-l-serine trilactone scaffold of enterobactin and bearing a 8-hydroxyquinoline (oxinobactin) or 8-hydroxyquinoline-5-sulfonate (sulfoxinobactin) unit has been described. The X-ray structure of the ferric oxinobactin has been determined, exhibiting a slightly distorted octahedral environment for Fe(III) and a Δ configuration. The Fe(III) chelating properties have been examined by potentiometric and spectrophotometric titrations in methanol-water 80/20% w/w solvent for oxinobactin and in water for sulfoxinobactin. They reveal the extraordinarily complexing ability (pFeIII values) of oxinobactin over the p[H] range 2-9, the pFe value at p[H] 7.4 being 32.8. This was supported by spectrophotometric competition showing that oxinobactin removes Fe(III) from ferric enterobactin at p[H] 7.4. In contrast, the Fe(III) affinity of sulfoxinobactin was largely lower as compared to oxinobactin but similar to that of the ligand O-TRENSOX having a TREN backbone. These results are discussed in relation to the predisposition by the trilactone scaffold of the chelating units. Some comparisons are also made with other quinoline-based ligands and hydroxypyridinonate ligand (hopobactin).

5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention aLso enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo- dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Oxinobactin, a siderophore analogue to enterobactin involving 8-hydroxyquinoline subunits: Synthesis and iron binding ability

Oxinobactin, a siderophore analogue to enterobactin but possessing 8-hydroxyquinoline instead of catechol complexing subunits, has been synthesized starting from l-serine and 8-hydroxyquinoline. Comparative iron binding studies showed that oxinobactin is as effective as enterobactin for the complexation of FeIII at physiological pH but with improved complexing ability at acidic pH.

COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS

The invention discloses aromatic amides and sulfonates to treat or prevent type 2 diabetes mellitus (T2DM), the pathological consequences of T2DM, to inhibit amyloidosis or to prevent death of β-cells of the pancreas.